Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

olerated. Frequency and severity of adverse events were similar to placebo, with no increase at higher doses. Among the Phase 2 study findings was a significantly improved response rate among serologically active patients at Week 52, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment (46% for LymphoStat-B versus 29% for placebo, p<0.01). This combination of measures is the primary efficacy endpoint in the Phase 3 clinical trials.

The data presented at EULAR 2007 demonstrated that LymphoStat-B continued to reduce the signs and symptoms of SLE disease activity throughout the 24- week extension phase of the study, demonstrated durable clinical and biological activity at Week 76, and appeared safe and well tolerated, with no increase in frequency and or severity of adverse events. The evidence of continuing improvement from Week 52 to Week 76 includes:

    -- An increase from 46% to 56% among serologically active patients in the

       patient response rate selected as the primary efficacy endpoint of the

       Phase 3 trials.


    -- An increase from 29% to 38% in the reduction in SLE disease activity

       among serologically active patients, as measured by SELENA SLEDAI.


    -- An increase from 33% to 41% in the reduction in SLE disease activity

       among serologically active patients, as measured by the Physician's

       Global Assessment.


    -- An increase in the mean improvement in health-related quality of life

       from 3.0 points to 3.4 points among serologically active patients, as

       measured by the SF-36 Physical Component Summary score.


    -- A durable reduction in anti-dsDNA autoantibodies (at least 50% or

       negative) among patients who were positive for anti-dsDNA at baseline

       (30% at Week 52; 34% at Week 76).


    -- Durable or increased reductions from Week 52 t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:3/5/2015)... 5, 2015 Vermillion, Inc. (Nasdaq: ... on gynecologic disease, announced today it will report ... market open on Wednesday, March 25, 2015, followed ... 8:30am Eastern. Conference Call & Webcast: ... Pacific Domestic: , 800-753-9057International: , 913-981-5571Conference ID: , ...
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
(Date:3/5/2015)... 5, 2015  Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" ... on developing, manufacturing, and acquiring cutting-edge technology, products and ... will be exhibiting at booth # 709 at the ... (NAPNAP) taking place on March 11-13, 2015 at Caesars ... The 36 th annual NAPNAP ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... Announces Clinical Trial Plans for 4Q07/1Q08, DALLAS, ... ACCP) provided today an update on the clinical,development ... prodrug, and,announced plans for additional human clinical trials ... ongoing clinical trial in recurrent ovarian,cancer patients, designed ...
... ... Study -, ... has initiated a multi-dose, Phase 2a clinical trial with,its monoclonal antibody ... dose-escalation study is,designed to evaluate the safety and tolerability of multiple ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 2Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 3Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 4MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma 2
(Date:3/5/2015)... 2015 HMP Communications Holdings ... and education, announced today its acquisition of the ... only medical conference designed for health care providers ... limb amputation due to vascular disorders. The ... evidence-based publications and CME activities across therapeutic fields ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... Leading nutritional supplement provider Metabolic Nutrition ... and Arnold Fitness EXPO in Columbus, Ohio ... a display booth featuring free samples of its superior ... class-leading fat burner Synedrex. The company will also be ... its top-of-the-line supplements and miniature action figures of its ...
(Date:3/5/2015)... Ill. (PRWEB) March 05, 2015 Think it’s ... be even tougher to get them to brush their teeth. ... 1,300 parents released today by Delta Dental(1) in conjunction with ... parents (45 percent) say getting kids to brush their teeth ... kids to do. That’s slightly higher than getting children to ...
(Date:3/5/2015)... DE (PRWEB) March 05, 2015 The ... false weight loss promises is alarming, with more and ... products without an actual prescription, making it easy for ... that simply take their money and endanger their health. ... questions before purchasing prescription online diet pills: , 1.    Where ...
Breaking Medicine News(10 mins):Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3
... 1 QED International Associates, Inc,administrator for the ... the HealthShares(TM) Exchange-Traded Funds, today announced,that effective at ... 2008,Analogic Corporation (Nasdaq: ALOG ) will replace ... the HealthShares(TM) Diagnostics Index. Ventana,s is,being acquired by ...
... Adults, HARRISBURG, Pa., Feb. 1 To help shape ... will host town meetings in Clarion, Feb. 7, and Pittsburgh, ... on Aging., "I urge older citizens to let us ... to shape the new State Plan on Aging. Their input ...
... interest and research on guayule and lesquerella, two native Big ... Texas, a Texas AgriLife Research scientist said. , Dr. Mike ... Extension Center at Lubbock, said he is looking at the ... the Trans-Pecos and High Plains. Foster, who is located at ...
... Feb. 1 Chiltern, the global contract research,organization, announced ... Solutions (,DDS,), a leading Phase 1 unit located at ... of the,United Kingdom,s major teaching hospitals. The purchase of ... DDS was founded in 1982 and has completed ...
... BLOOMINGTON, Minn., Feb. 1 -- HealthPartners contracts with ... who work in HealthPartners Clinics, expired yesterday at,11:59 ... HealthPartners offer to SEIU included:, -- A ... of the contract., -- Maintaining fully-paid individual ...
... Special Committee on Aging held a hearing yesterday in ... they face in exercising their right to vote. Jason ... at the University of Pennsylvania School of Medicine, testified ... his studies examining voting rights for the elderly. Karlawish, ...
Cached Medicine News:Health News:Pennsylvania Department of Aging Plans Town Meetings in Clarion and Pittsburgh to Gather Input for New State Plan on Aging 2Health News:Growing markets bring potential for rubber and oilseed crops 2Health News:Growing markets bring potential for rubber and oilseed crops 3Health News:Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS) 2Health News:Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS) 3Health News:Older Americans suffer serious access limitations to exercise their right to vote 2Health News:Older Americans suffer serious access limitations to exercise their right to vote 3
... Artis dTC is a versatile solution designed ... department from preparation to diagnosis and ... With AXIOM Artis dTC, your cath lab ... department that leaves you free to concentrate ...
... BC is a biplane cardiovascular ... ideal for cardiological diagnostics and ... architecture enables you to optimally ... focus on:, Interventional cardiology, ...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
... you to scan every beating heart at any ... possible. A scanner using two X-ray sources ... provides one-stop diagnosis in acute care; even with ... Combined with the Cardiac Engine, a unique combination ...
Medicine Products: